Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27021040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Vittoria Maresca und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomic Research, San Gallicano Dermatological Institute, IRCCS, 00144 Rome, Ita…. Hauptthemen laut MEDLINE: Lipidomics, Melanoma, Lipid Metabolism, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 314 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by public funds from the Italian Ministry of Health (RC2026)..
Abstract (Originalsprache)
Melanoma is the deadliest form of skin cancer, characterized by high metastatic potential and intrinsic heterogeneity. In addition to genetic mutations such as BRAF^V600E^ and NRAS, lipid metabolic reprogramming has emerged as a critical factor in tumor progression and therapy resistance. Lipid metabolism supports melanoma cell survival, phenotypic switching, immune evasion, and resistance to targeted therapies and immunotherapy, while also modulating susceptibility to ferroptosis. This review summarizes current knowledge on lipid dysregulation in melanoma, highlighting alterations in fatty acid synthesis, desaturation, uptake, storage, and oxidation, as well as changes in phospholipids, sphingolipids, cholesterol, and bioactive lipid mediators. These lipid pathways are tightly regulated by oncogenic signaling networks, including MAPK and PI3K–AKT–mTOR pathways, and are influenced by tumor microenvironmental stressors such as hypoxia and nutrient limitation. Advances in lipidomics technologies, particularly mass spectrometry-based approaches, have enabled comprehensive profiling of lipid alterations at bulk, spatial, and single-cell levels, offering new opportunities for biomarker discovery and therapeutic stratification. Targeting lipid metabolic vulnerabilities represents a promising strategy to improve melanoma diagnosis, prognosis, and treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomic Research, San Gallicano Dermatological Institute, IRCCS, 00144 Rome, Italy.
ORCID-Profile: Emanuela Bastonini, Giorgia Cardinali, Enrica Flori, Monica Ottaviani
Förderung
- This work was supported by public funds from the Italian Ministry of Health (RC2026).
Zitieren
APA
Maresca, V., Bastonini, E., Cardinali, G., Flori, E., Kovacs, D., Ottaviani, M., & Briganti, S. (2026). Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27021040
Vancouver
Maresca V, Bastonini E, Cardinali G, Flori E, Kovacs D, Ottaviani M, et al. Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27021040
BibTeX
@article{Maresca2026,
author = {Maresca, Vittoria and Bastonini, Emanuela and Cardinali, Giorgia and Flori, Enrica and Kovacs, Daniela and Ottaviani, Monica and Briganti, Stefania},
title = {Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27021040}
}
EUVIMED